Apple, Novocure, Dynavax Technologies News Today

Apple, Novocure, and Dynavax Technologies are in the news today

Apr 3, 2017 at 9:58 AM
facebook X logo linkedin

Stocks are trading modestly higher to start the second quarter. Among specific equities in focus are iPhone maker Apple Inc. (NASDAQ:AAPL), as well as cancer specialists Novocure Ltd (NASDAQ:NVCR) and Dynavax Technologies Corporation (NASDAQ:DVAX). Here's a quick roundup of the news moving shares of AAPL, NVCR, and DVAX today.

Apple Stock Rises After Imagination Technologies Snub

Wall Street is buzzing on Apple news, after the company said it will begin making its own "independent graphics design in order to control its own products" -- and will terminate its graphic licensing deal with U.K.'s Imagination Technologies in roughly two years. While shares of the latter have plunged nearly 62% in London, AAPL stock is is trading up 0.1% at $143.79 -- coming within a chip-shot of its March 30 record high of $144.50. Longer term, Apple Inc shares have swung more than 24% higher in 2017, yet seven of 30 analysts still maintain a "hold" or "strong sell" recommendation. Another round of bullish brokerage notes could propel AAPL stock further into uncharted territory.

Novocure Shares Surge on Pancreatic Cancer Drug Data

NVCR stock has shot 50% higher to trade at $12.20 -- easily taking out recent resistance at its 200-day moving average. Boosting the shares is positive combination therapy data for Novocure Ltd's pancreatic cancer treatment. The stock has now more than doubled in value since hitting a year-to-date low of $6 in late January, and short sellers are likely feeling the heat. Though short interest fell 2.7% in the most recent reporting period, it still accounts for a lofty 14.2% of NVCR's available float. What's more, it would take almost a month to cover these bearish bets, at the stock's average pace of trading, meaning there's plenty of sideline cash available to help fuel NVCR's fire. 

FDA Review Date for Hep B Vaccine Fails to Lift Dynavax Technologies Stock

Shares of DVAX are trading down 1.7% at $5.85, even after the biotech said the Food and Drug Administration (FDA) will review its hepatitis B vaccine on Friday, July 28, with the decision date slated for Thursday, Aug. 10. Last November, DVAX stock plunged to a nearly eight-year low of $3.20 after the FDA rejected the vaccine, but the shares have more than doubled in the subsequent months. Short sellers, meanwhile, have been in covering mode. Since topping out at a multi-year peak in early November, short interest on Dynavax Technologies Corporation has fallen nearly 38% -- though these bearish bets still account for almost 19% of DVAX's float.

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI